Would you consider OFS in a young patient (<35) with ER+ breast cancer who required chemotherapy and menses resumed years later while on tamoxifen?
If the cancer was also HER2+, would that influence your decision?
Community PollStarted
Would you offer OFS in a young patient (<35) with ER+ breast cancer who required chemotherapy and menses resumed years later while on tamoxifen?
71 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · H Lee Moffitt Cancer Center, University of South Florida
Answered on
The SOFT/TEXT trial demonstrated a DFS/OS benefit for OFS when added to endocrine therapy. Patients at higher risk (<35 years old, node +, treated with chemotherapy) would likely benefit more. The decision to do this depends on her baseline risk. The HER2 status is interesting in that HER2- patients...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Sarah Cannon Research Institute
Answered on
The survival benefit for OS is among LN + patients, not LN-. So, it would depend on clinical risk and nodal status for me. If she is node negative, odds are she will not get substantial benefit over tamoxifen alone.
Join for free or sign in to see the full answer